Cormorant Asset Management, LP's Net Worth

$1.28 Billion

Estimate Recalculated Feb 27, 2024 06:01PM EST

Who is Cormorant Asset Management, LP?

Cormorant Asset Management, LP has an estimated net worth of $1.28 Billion. This is based on reported shares across multiple companies, which include Corbus Pharmaceuticals Holdings, Inc., Turning Point Therapeutics, Inc., Vigil Neuroscience, Inc., Prometheus Biosciences, Inc., Ambrx Biopharma, Inc., Design Therapeutics, Inc., Kezar Life Sciences, Inc., Icosavax, Inc., Atea Pharmaceuticals, Inc., Kiniksa Pharmaceuticals, Ltd., Ventyx Biosciences, Inc., Axonics Modulation Technologies, Inc., Tyra Biosciences, Inc., Erasca, Inc., Monte Rosa Therapeutics, Inc., Verve Therapeutics, Inc., Aerovate Therapeutics, Inc., Avidity Biosciences, Inc., Apellis Pharmaceuticals, Inc., Immuneering Corp, Pyxis Oncology, Inc., Elevation Oncology, Inc., PROTEOSTASIS THERAPEUTICS, INC., BioAtla, Inc., Ambrx Biopharma Inc., Biomea Fusion, Inc., Rain Therapeutics Inc., Akouos, Inc., Cellectar Biosciences, Inc., Olema Pharmaceuticals, Inc., Clearside Biomedical, Inc., GreenLight Biosciences Holdings, PBC, CONSTELLATION PHARMACEUTICALS INC, MoonLake Immunotherapeutics, and EyePoint Pharmaceuticals, Inc..

SEC CIK

Cormorant Asset Management, LP's CIK is 0001583977

Past Insider Trading and Trends

2023 was Cormorant Asset Management, LP's most active year for acquiring shares with 37 total transactions. Cormorant Asset Management, LP's most active month to acquire stocks was the month of November. 2021 was Cormorant Asset Management, LP's most active year for disposing of shares, totalling 15 transactions. Cormorant Asset Management, LP's most active month to dispose stocks was the month of October. 2023 saw Cormorant Asset Management, LP paying a total of $207,445,307.04 for 15,599,466 shares, this is the most they've acquired in one year. In 2023 Cormorant Asset Management, LP cashed out on 9,188,659 shares for a total of $0.00, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Snapshot price: $25.9

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+103.45%
750K
$19.00
$14,250,000.00
1.48M
Feb 2
Form 4
+63.89%
282.63K
$32.24
$9,111,940.74
725K
Jan 26
Form 3
0
0
No matching records found

Turning Point Therapeutics, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
0
0
Form 4
+0.75%
23.27K
$2.19
$51,061.63
3.12M
May 13 - May 14
Form 3
0
0
Form 4
+14.82%
400K
$18.00
$7,200,000.00
3.1M
Apr 22
No matching records found

Vigil Neuroscience, Inc. (VIGL) Snapshot price: $2.8652

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
616.79K
616.79K
Jan 11
Form 3
0
0
No matching records found

Prometheus Biosciences, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
2.22M
$19.00
2.22M
Mar 16
Form 3/A
0
0
Form 3
0
0
No matching records found

Ambrx Biopharma, Inc. (AMAM) Snapshot price: $27.78

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+13.17%
1.31M
$6.99
$9,139,541.93
11.23M
Oct 23
No matching records found